Trending

Opdivo

Opdivo and Keytruda approved in new lung cancer uses

Opdivo and Keytruda approved in new lung cancer uses

The FDA has approved Merck’s Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer

X

Opdivo and Keytruda approved in new lung cancer uses

https://pharmaphorum.com/news/bmss-opdivo-approved-lung-cancer/

Merck & Co’s Keytruda shows potential in head and neck cancer use

Merck & Co’s Keytruda shows potential in head and neck cancer use

Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head

X

Merck & Co’s Keytruda shows potential in head and neck cancer use

https://pharmaphorum.com/news/keytruda-shows-promise-first-line-skin-cancer-treatment/

BMS strikes back with lung cancer combo success

BMS strikes back with lung cancer combo success

Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.

X

BMS strikes back with lung cancer combo success

https://pharmaphorum.com/news/bms-strikes-back-lung-cancer-combo-success/

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy

X

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

https://pharmaphorum.com/news/bms-infinity-aim-overcome-triple-negative-breast-cancer-resistance-io/

BMS and Roche look to Halozyme drug delivery for IO advantage

BMS and Roche look to Halozyme drug delivery for IO advantage

Bristol-Myers Squibb is to work with drug delivery specialist Halozyme to create an injectable form of its blockbuster

X

BMS and Roche look to Halozyme drug delivery for IO advantage

https://pharmaphorum.com/news/bms-roche-look-halozyme-drug-delivery-io-advantage/

Clovis and BMS combine cancer drugs in late-stage trials

Clovis and BMS combine cancer drugs in late-stage trials

Clovis and BMS research small molecule and antibody combination.

X

Clovis and BMS combine cancer drugs in late-stage trials

https://pharmaphorum.com/news/clovis-bms-cancer/

Scotland decision helps Opdivo in UK market access picture

Scotland decision helps Opdivo in UK market access picture

The last 18 months has seen groundbreaking cancer immunotherapies, led by BMS’s Opdivo and Merck Sharp & Dohme’s

X

Scotland decision helps Opdivo in UK market access picture

https://pharmaphorum.com/news/scotland-decision-helps-opdivo-uk-market-access-picture/

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patients

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patients

Bristol-Myers Squibb is teaming up with France’s Transgene to combine Opdivo with investigational therapeutic vaccine TG4010 in lung

X

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patients

https://pharmaphorum.com/news/bms-looks-opdivo-cancer-vaccine-combination-regain-ground-nsclc/

NICE rejects Opdivo in head and neck cancer – before it gains marketing approval

NICE rejects Opdivo in head and neck cancer – before it gains marketing approval

England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in

X

NICE rejects Opdivo in head and neck cancer – before it gains marketing approval

https://pharmaphorum.com/news/nice-rejects-opdivo-head-neck-cancer-gains-marketing-approval/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com